Hikma Launches First US Sodium Acetate With CGT Exclusivity

The Firm Plans Two Further Launches Of Different Concentrations

Following on from a flurry of deal and launches, Hikma has released another product onto the US market with the first of its sodium acetate injections, bolstered by 180 days of Competitive Generic Therapy exclusivity. 

An image of Hikma's logo
• Source: Shutterstock

More from Generics

More from Products